Related Experiment Video
Updated: Jun 20, 2026

Fine-tuning the Size and Minimizing the Noise of Solid-state Nanopores
Published on: November 1, 2013
Donanemab: Appropriate use recommendations
G D Rabinovici1, D J Selkoe2, S E Schindler3
1Memory & Aging Center, Departments of Neurology, Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Donanemab is approved for early Alzheimer's disease (AD). These recommendations guide its safe and effective use in clinical practice, focusing on patient selection and monitoring for side effects like ARIA.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Donanemab is an approved IgG1 monoclonal antibody for early symptomatic Alzheimer's disease (AD).
- Appropriate Use Recommendations (AUR) are crucial for guiding donanemab's real-world implementation.
- Prioritizing safety and effectiveness is key for patient management.
Purpose of the Study:
- To establish guidelines for the appropriate use of donanemab in clinical practice.
- To define patient eligibility criteria and safety monitoring protocols for donanemab therapy.
- To integrate expert opinion and available data for optimal donanemab administration.
Main Methods:
- Development of AUR by the AD and Related Disorders Therapeutic Workgroup through consensus.
- Integration of current data and expert clinical judgment.
- Definition of patient profiles, including biomarker confirmation and exclusion criteria.
Main Results:
- Appropriate candidates: Mild cognitive impairment or mild dementia due to AD (Clinical Stages 3-4, MMSE 20-30) with confirmed AD pathology (PET or CSF).
- Safety considerations: APOE genotyping recommended; MRI pre-treatment required; exclusion criteria include specific vascular findings and microbleeds.
- Monitoring: Surveillance MRIs for ARIA before specific infusions and as clinically indicated; potential treatment discontinuation upon amyloid clearance.
Conclusions:
- Donanemab AUR provide a framework for safe and effective treatment of early symptomatic AD.
- Shared decision-making is essential, considering patient values and goals of care.
- Careful patient selection, monitoring for ARIA, and consideration of amyloid clearance guide long-term management.
Related Concept Videos
Range Rule of Thumb to Interpret Standard Deviation
For instance, the range rule of thumb can be used to find the tallest and the shortest student in a class, given the mean student height and standard deviation. If the mean student height is 1.6 m and the standard deviation, s is 0.05 m, the height of...
Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Legal Guidelines for Documentation
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Design Consideration
The factor of safety is another key aspect...
Methods of Medium Optimization

